Endogenex

Endogenex is #hiring. Looking to bring your expertise and passion for transformative healthcare to a company on the forefront of developing therapies for people living with Type 2 Diabetes, this may be it. Learn more https://lnkd.in/eVUjfHXw

Expanded REGENT-1 clinical study outcomes published at #ADC2024. Congratulations to Dr. John Apostolopoulos and the Diabetes Technology Research Group for your hard work and presentation. #type2diabetes #gastroenterology #endocrinology #ReCET #diabetesresearch #diabetestechnology #diabetesmanagement

Our D.T.R.G 2024 research scholarship recipient and research fellow Dr John Apostolopoulos presenting his two projects at #ADC2024. John presented on the Regent study, investigating the feasibility of a novel treatment for type 2 diabetes using duodenal mucosal re-celluarization, and the MEWS study, evaluating a novel extended wear sensor. Both projects have provided positive results. Endogenex Medtronic University of Melbourne St Vincent's Hospital Melbourne The BMI Clinic // The Bariatric & Metabolic Institute Austin Health #diabetes #diabetestechnology #diabetesresearch #diabetescare #t1d #t2d

Endogenex is #hiring. Looking to bring your expertise and passion for transformative healthcare to a company on the forefront of developing therapies for people living with Type 2 Diabetes, this may be it. Learn more https://lnkd.in/eVUjfHXw

StarTribune Business highlights the rebound in investment for healthcare startups in Minnesota. The Endogenex team is pleased to be included in the dialogue supporting the incredible Minnesota Med Tech community. #Endogenex #ReCET #type2diabetes #endocrinology #gastroenterology https://lnkd.in/eJKXjKW2

Sunday Funday! Let's talk #MedTech news! Congratulations to NeuroBionics for being named the 2024 Vision Award Winner by live audience vote at Wilson Sonsini Goodrich & Rosati 31st Annual Medical Device Digital Health Conference! This MedTech Innovator company is focused on minimally-invasive #endovascular deep brain stimulation. Nicolette Driscoll Marc-Joseph Antonini Ronovo Surgical announced a $44 Mil Series B funding round to commercialize its #robotic assisted #surgery platform. John Ma, Ph.D. VenoStent, Inc. closed an additional $4 Mil to round out $20 Mil Series A, a company developing bioengineered polymers for #vascular surgery. Timothy Boire Paragonix Technologies, Inc. launched their #pancreas preservation system, becoming the first #FDA cleared device designated to protect and monitor donated pancreases during transportation. Lisa Anderson ICHOR Vascular Inc. closed its Series A, progressing their peripheral clot removal platform for #PAD #peripheral artery disease. Tim Blair Neurolief announced positive trial results for their #depression technology. Scott F Drees NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) completed its first human neuroablation treatment procedures. Dave Rosa Endotronix announced FDA approval of their Cordella Pulmonary Artery (PA) Sensor System to treat New York Heart Failure (NYHA) class III heart failure patients. Harry Rowland AliveCor announced it received FDA clearance for its Kardia 12L (12-lead) #ECG (#electrocardiogram) system. Priya Abani Lots of action in #Diabetes as #ADA2024 took place in Orlando, FL. Highlights include greater #sensor capabilities in #CGM tech, #GLP1 drugs and more. Check out Sean Whooley's articles for full coverage. Which brings me to my favorite read of the week. Seeing the $88 Mil raise for Endogenex is encouraging we are moving away from exclusively managing diabetes as a chronic condition, but rather seeking a cure. Congratulations to Stacey Pugh and team in this outstanding effort. As always, THANK YOU LSI, MassDevice, MassMEDIC MedTech Dive and the many friends sharing great news in our industry. Have a great week! https://lnkd.in/eHdFbdiH

Congratulations to Longitude portfolio company Endogenex on its recent $88 million Series C financing! Endogenex is a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes. With the financing, the company will complete the ReCET Clinical Study, which has been granted an Investigational Device Exemption by the U.S. FDA. “We are very proud of the company’s progress, and this successful funding round is a testament to Endogenex’s innovative technology,” said Juliet Tammenoms Bakker, Endogenex Board Chair and Longitude Capital Managing Director. “This milestone underscores our investors’ confidence in the company’s vision, and the impact it can make in treating the epidemic of type 2 diabetes around the world.” Learn more about the new capital and the ReCET clinical study: https://lnkd.in/dprt3Spy #type2diabetes #medicaldevices #venturecapital

We would like to congratulate Steve Flint for his outstanding presentation at the recent Australian Diabetes Educators Association Victorian State Conference for 2024. Steve presented the preliminary findings of the ReCET study undertaken in collaboration with Endogenex, which investigated a novel treatment for Type 2 Diabetes through duodenum recellularization. #type2diabetes #diabetesresearch #ADEA2024

Diabetes Technology Research Group are delighted to see our Director, Prof David O'Neal, presenting the Australian data from the Regent project by Endogenex at American Diabetes Association #ADA2024 Georgina Manos Elif Ekinci Lian Cunningham #diabetesresearch #diabetestechnology #t2d

🌟 Breaking News: Endogenex secures $88M Series C funding led by strategic investors, including Hatteras Venture Partners and Lumira Ventures, to advance groundbreaking diabetes treatment. CEO Stacey Pugh excitedly shares, "This milestone accelerates our mission to transform diabetes care." #HealthInnovation #DiabetesResearch https://lnkd.in/geTgkP6a